The Transcriptomic Pathways of the FPL Lifestyle Accompanied with the Use of Lomaira in Latino Families with the Disease of Obesity -a pilot study
Grantee: Loma Linda University
Year Funded: 2024
Amount: $70,000
Report Status: In Process
Related Content:
Project Summary: The goal is to recruit 50 teams of toddlers with obesity and parent/primary care provider (PCP) with obesity in which the toddler spends at least 50% of their waking hours with the parent/grandparent that well be treated for obesity with “pharmaceutically supported lifestyle changes. This is a 36-week randomized, proof of concept, study using the Full Plate Living (FPL) lifestyle training plus either placebo or active Lomaira™ phentermine 8 mg one to three times per day.
Primary endpoints:
Toddler – Improved BMI percentiles
Parents
A. Lower BMI
B. Improved metabolic variables
Secondary endpoints – Parent’s/PCP -transcriptomics (“omic” understanding the mechanisms of weight management through nutrition and pharmaceutically supported lifestyle changes with Lomaira™
Innovation:
Many parent and child studies have been done but, to our knowledge this is first to use pharmaceutically supported lifestyle changes.
Phentermine is the obesity medication that is most commonly available for people that do not have health insurance or their insurance does not cover obesity medications. Because of its low cost, $26.00 for 100 37.5mg tablets, phentermine has become an “orphan” pharmaceutical. Since 1959, it has proven to create and maintain weight loss, but it’s mechanisms of action in humans has not been studied. This will be the first transcriptomics evaluation of Full Plate Lifestyle alone and with Lomaira™ phentermine, in adults with the disease of obesity.
